Cargando…
Serology in COVID-19: Comparison of Two Methods †
Background: The aim of our study was to examine the performance of two assays in detecting SARS-CoV-2 antibodies. Methods: A total of 127 COVID-19 disease contacts from the Infectious Diseases Department were included. Two serological tests were used: SARS-CoV-2 IgG CMIA on the Alinity system (Abbot...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296394/ https://www.ncbi.nlm.nih.gov/pubmed/34208607 http://dx.doi.org/10.3390/ijerph18126497 |
_version_ | 1783725628489465856 |
---|---|
author | Moniuszko-Malinowska, Anna Jelski, Wojciech Dunaj, Justyna Mroczko, Barbara Czupryna, Piotr Kruszewska, Ewelina Pancewicz, Sławomir |
author_facet | Moniuszko-Malinowska, Anna Jelski, Wojciech Dunaj, Justyna Mroczko, Barbara Czupryna, Piotr Kruszewska, Ewelina Pancewicz, Sławomir |
author_sort | Moniuszko-Malinowska, Anna |
collection | PubMed |
description | Background: The aim of our study was to examine the performance of two assays in detecting SARS-CoV-2 antibodies. Methods: A total of 127 COVID-19 disease contacts from the Infectious Diseases Department were included. Two serological tests were used: SARS-CoV-2 IgG CMIA on the Alinity system (Abbott) and LIAISON(®) SARS-CoV-2 S1/S2 IgG CLIA (DiaSorin). Results: The assays exhibited a 96.85% (123/127 patients) test result agreement. In two cases, the positive results obtained by SARS-CoV-2 IgG CMIA on the Alinity system (Abbott) were negative based on the LIAISON(®) SARS-CoV-2 S1/S2 IgG CLIA (DiaSorin) test, and in two cases, negative results from the LIAISON(®) SARS-CoV-2 S1/S2 IgG CLIA (DiaSorin) test were positive with the SARS-CoV-2 IgG CMIA on the Alinity system (Abbott). Conclusions: Based on the results of our study, we conclude that in population medicine, the assessments of anti-SARS-CoV-2 antibodies after exposure to SARS-CoV-2 virus based on spike protein or nucleocapsid protein show comparable effectiveness. |
format | Online Article Text |
id | pubmed-8296394 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82963942021-07-23 Serology in COVID-19: Comparison of Two Methods † Moniuszko-Malinowska, Anna Jelski, Wojciech Dunaj, Justyna Mroczko, Barbara Czupryna, Piotr Kruszewska, Ewelina Pancewicz, Sławomir Int J Environ Res Public Health Brief Report Background: The aim of our study was to examine the performance of two assays in detecting SARS-CoV-2 antibodies. Methods: A total of 127 COVID-19 disease contacts from the Infectious Diseases Department were included. Two serological tests were used: SARS-CoV-2 IgG CMIA on the Alinity system (Abbott) and LIAISON(®) SARS-CoV-2 S1/S2 IgG CLIA (DiaSorin). Results: The assays exhibited a 96.85% (123/127 patients) test result agreement. In two cases, the positive results obtained by SARS-CoV-2 IgG CMIA on the Alinity system (Abbott) were negative based on the LIAISON(®) SARS-CoV-2 S1/S2 IgG CLIA (DiaSorin) test, and in two cases, negative results from the LIAISON(®) SARS-CoV-2 S1/S2 IgG CLIA (DiaSorin) test were positive with the SARS-CoV-2 IgG CMIA on the Alinity system (Abbott). Conclusions: Based on the results of our study, we conclude that in population medicine, the assessments of anti-SARS-CoV-2 antibodies after exposure to SARS-CoV-2 virus based on spike protein or nucleocapsid protein show comparable effectiveness. MDPI 2021-06-16 /pmc/articles/PMC8296394/ /pubmed/34208607 http://dx.doi.org/10.3390/ijerph18126497 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Moniuszko-Malinowska, Anna Jelski, Wojciech Dunaj, Justyna Mroczko, Barbara Czupryna, Piotr Kruszewska, Ewelina Pancewicz, Sławomir Serology in COVID-19: Comparison of Two Methods † |
title | Serology in COVID-19: Comparison of Two Methods † |
title_full | Serology in COVID-19: Comparison of Two Methods † |
title_fullStr | Serology in COVID-19: Comparison of Two Methods † |
title_full_unstemmed | Serology in COVID-19: Comparison of Two Methods † |
title_short | Serology in COVID-19: Comparison of Two Methods † |
title_sort | serology in covid-19: comparison of two methods † |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296394/ https://www.ncbi.nlm.nih.gov/pubmed/34208607 http://dx.doi.org/10.3390/ijerph18126497 |
work_keys_str_mv | AT moniuszkomalinowskaanna serologyincovid19comparisonoftwomethods AT jelskiwojciech serologyincovid19comparisonoftwomethods AT dunajjustyna serologyincovid19comparisonoftwomethods AT mroczkobarbara serologyincovid19comparisonoftwomethods AT czuprynapiotr serologyincovid19comparisonoftwomethods AT kruszewskaewelina serologyincovid19comparisonoftwomethods AT pancewiczsławomir serologyincovid19comparisonoftwomethods |